Adverse Events, Comorbidities, and HIV

April 15, 2021: Alcohol and neurocognitive impairment; using hair analysis to measure substance use; integrase inhibitors' impact on verbal learning; hepatocellular carcinoma trends among PLWH.

Here's a walkthrough of some of the most compelling stories coming out of the year's biggest HIV science meeting to date.

Helping my longtime friend Jeremy find such trials alerted me to this ongoing problem—which will only be reversed if patients, doctors, and trial reviewers keep pushing back on Pharma.

David Alain Wohl, M.D., on new findings from CROI 2021 that help us better understand the connections between sleep, diet, and quality of life among people living with HIV.

David Alain Wohl, M.D., talks through new data presented at CROI 2021 that further our understanding of the interplay between HIV and comorbidities we often associate with aging, particularly those related to cardiovascular disease.

David Alain Wohl, M.D., analyzes updated data regarding the intersection of HIV and COVID-19, with a particular focus on SARS-CoV-2 susceptibility and disease severity.

New research suggests a high prevalence of hepatitis D, the most severe form of viral hepatitis, in PLWH in regions of Europe, and a particularly high risk for people who inject drugs.

March 25, 2021: HIV disease progression spikes in a London hospital; neurocognitive impairment and frailty in PLWH; the smell of HIV-associated neurocognitive disorder; statin usage and physical function decline.

The incidence of anal cancer is rapidly growing in the United States, and may overtake cervical cancer within the next 10 years.

March 18, 2021: Improving viral suppression among PLWH experiencing homelessness; co-located PrEP services for trans women; subsidized health care and PrEP uptake; Heplisav-B hepatitis B vaccine efficacy in PLWH.